| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 5077 | 2016 |
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer MR Posner, DM Hershock, CR Blajman, E Mickiewicz, E Winquist, ... New England Journal of Medicine 357 (17), 1705-1715, 2007 | 2139 | 2007 |
| Recent advances in head and neck cancer RI Haddad, DM Shin New England Journal of Medicine 359 (11), 1143-1154, 2008 | 1172 | 2008 |
| Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology DG Pfister, S Spencer, D Adelstein, D Adkins, Y Anzai, DM Brizel, ... Journal of the National Comprehensive Cancer Network 18 (7), 873-898, 2020 | 991 | 2020 |
| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838-3845, 2016 | 900 | 2016 |
| Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck … R Haddad, A O'Neill, G Rabinowits, R Tishler, F Khuri, D Adkins, J Clark, ... The lancet oncology 14 (3), 257-264, 2013 | 807 | 2013 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 797 | 2018 |
| Head and neck cancers, version 2.2014 DG Pfister, S Spencer, DM Brizel, B Burtness, PM Busse, JJ Caudell, ... Journal of the National Comprehensive Cancer Network 12 (10), 1454-1487, 2014 | 746 | 2014 |
| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542-1549, 2017 | 704 | 2017 |
| Head and neck cancer MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba The Lancet 398 (10318), 2289-2299, 2021 | 604 | 2021 |
| NCCN guidelines insights: head and neck cancers, version 1.2018 AD Colevas, SS Yom, DG Pfister, S Spencer, D Adelstein, D Adkins, ... Journal of the National Comprehensive Cancer Network 16 (5), 479-490, 2018 | 600 | 2018 |
| Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial MR Posner, JH Lorch, O Goloubeva, M Tan, LM Schumaker, NJ Sarlis, ... Annals of oncology 22 (5), 1071-1077, 2011 | 560 | 2011 |
| Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ... Nature genetics 50 (9), 1271-1281, 2018 | 548 | 2018 |
| Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results … JH Lorch, O Goloubeva, RI Haddad, K Cullen, N Sarlis, R Tishler, M Tan, ... The lancet oncology 12 (2), 153-159, 2011 | 527 | 2011 |
| Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum … JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ... The Lancet Oncology 16 (5), 583-594, 2015 | 475* | 2015 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer 119 (2), 153-159, 2018 | 472 | 2018 |
| Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised … NY Lee, RL Ferris, A Psyrri, RI Haddad, M Tahara, J Bourhis, K Harrington, ... The Lancet Oncology 22 (4), 450-462, 2021 | 460 | 2021 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 447 | 2017 |
| Characterization of HPV and host genome interactions in primary head and neck cancers M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ... Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014 | 447 | 2014 |
| NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines JJ Caudell, ML Gillison, E Maghami, S Spencer, DG Pfister, D Adkins, ... Journal of the National Comprehensive Cancer Network 20 (3), 224-234, 2022 | 377 | 2022 |
Robert L. FerrisUniversity of PittsburghПотвърден имейл адрес: upmc.edu
